Abeona Therapeutics Inc. (ABEO) Rating Reiterated by Cantor Fitzgerald
Cantor Fitzgerald reiterated their buy rating on shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) in a report published on Friday morning. They currently have a $21.00 price objective on the biopharmaceutical company’s stock.
A number of other equities analysts also recently issued reports on the stock. Rodman & Renshaw reiterated a buy rating and issued a $17.00 price target on shares of Abeona Therapeutics in a report on Friday, August 5th. Maxim Group reissued a buy rating and issued a $6.00 price objective on shares of Abeona Therapeutics in a research note on Tuesday, August 2nd. Zacks Investment Research raised shares of Abeona Therapeutics from a sell rating to a hold rating in a research note on Wednesday, July 20th. Finally, FBR & Co reissued a buy rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a research note on Friday, August 26th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. Abeona Therapeutics has a consensus rating of Buy and an average target price of $14.50.
Shares of Abeona Therapeutics (NASDAQ:ABEO) opened at 6.69 on Friday. The stock has a 50 day moving average of $5.08 and a 200-day moving average of $3.35. Abeona Therapeutics has a 1-year low of $2.05 and a 1-year high of $7.00. The stock’s market capitalization is $224.42 million.
Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by $0.06. Abeona Therapeutics had a negative net margin of 2,177.03% and a negative return on equity of 30.84%. Equities research analysts predict that Abeona Therapeutics will post ($0.73) earnings per share for the current fiscal year.
In other news, Director Todd Wider purchased 5,000 shares of the firm’s stock in a transaction on Tuesday, September 20th. The shares were bought at an average cost of $5.48 per share, with a total value of $27,400.00. Following the purchase, the director now directly owns 75,000 shares of the company’s stock, valued at $411,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 13.00% of the stock is currently owned by corporate insiders.
Several large investors have recently added to or reduced their stakes in ABEO. Geode Capital Management LLC boosted its stake in Abeona Therapeutics by 16.7% in the first quarter. Geode Capital Management LLC now owns 70,496 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 10,082 shares in the last quarter. BlackRock Fund Advisors boosted its stake in Abeona Therapeutics by 8.5% in the first quarter. BlackRock Fund Advisors now owns 302,262 shares of the biopharmaceutical company’s stock valued at $774,000 after buying an additional 23,734 shares in the last quarter. Sabby Management LLC boosted its stake in Abeona Therapeutics by 11.4% in the first quarter. Sabby Management LLC now owns 334,108 shares of the biopharmaceutical company’s stock valued at $855,000 after buying an additional 34,108 shares in the last quarter. Finally, Royce & Associates LP boosted its stake in Abeona Therapeutics by 25.6% in the first quarter. Royce & Associates LP now owns 376,321 shares of the biopharmaceutical company’s stock valued at $963,000 after buying an additional 76,678 shares in the last quarter. 19.95% of the stock is currently owned by institutional investors.
Abeona Therapeutics Company Profile
Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.